Skip to content
Screener

Total Revenue at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$25.31B+6.6%
Glaukos logo
GlaukosGKOS
$185.61M+49.5%
AbbVie logo
AbbVieABBV
$16.99B+10.2%
Bausch + Lomb logo
Bausch + LombBLCO
$1.39B+9.1%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$173.91M+69.4%
Boston Scientific logo
Boston ScientificBSX
$5.44B+7.5%

Segments

By segment

See full
Surgical Glaucoma$20.71M+7.7%
Dry Eye$2.68M+703%

Other financials

Income statement

See full
Gross profit$21.4M+28.9%
Operating income-$3.9M+66.7%
Net income-$4.4M+62.8%
EPS (diluted)-$0.08+65.2%

Balance sheet

See full
Cash & equivalents$79.8M-21.4%
Total debt$41.2M+1.5%
Total equity$52.9M-24.5%
Total assets$104.9M-14.0%

Cash flow

See full
Operating cash flow-$5.7M+24.9%
CapEx$19.0K-91.0%
Free cash flow-$5.7M+26.7%

Valuation

See full
Market cap$445.11M+130%
Enterprise value$406.53M+207%
P/S5.3×+2.8×

Profitability

See full
Gross margin88%+2.6pp
Operating margin-33.4%-10.8pp
Net margin-35.7%-11.0pp
FCF margin-28%-1.8pp

Returns & leverage

See full
Return on equity-48.4%-6.4pp
Debt / equity0.8×+0.2×
Current ratio4.9×-5.1×

Where this comes from

Reported directly by Sight Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Sight Sciences, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335204
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$23,388$19,564$43,086$37,072
Cost of goods sold2,0142,9774,7345,391
Gross profit21,37416,58738,35231,681
Operating expenses:
Research and development2,5124,3875,0588,817
Selling, general and administrative22,75023,86749,59548,390
Total operating expenses25,26228,25454,65357,207
Loss from operations(3,888)(11,667)(16,301)(25,526)

Item 1. Financial Statements

FAQ

What is Sight Sciences, Inc.'s total revenue?
Sight Sciences, Inc. (SGHT) reported total revenue of $23.39M in Q2 2026.
How has Sight Sciences, Inc.'s total revenue changed year-over-year?
Sight Sciences, Inc.'s total revenue increased by 19.5% year-over-year, from $19.56M to $23.39M.
What is the long-term trend for Sight Sciences, Inc.'s total revenue?
Over 4 years (2021 to 2025), Sight Sciences, Inc.'s total revenue has grown at a 12.1% compound annual growth rate (CAGR), from $48.96M to $77.36M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Sight Sciences, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude